Besides, the results from our Western blotting also showed that NAT-F treatment significantly up-regulated Bax and down-regulated Bcl-2, Bcl-xL, and Mcl-1 in both NSCLC cells. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.